| Literature DB >> 26694031 |
Helena Dreber1, Signy Reynisdottir1, Bo Angelin2, Erik Hemmingsson1.
Abstract
OBJECTIVE: To characterize treatment-seeking young adults (16-25 years) with severe obesity, particularly mental health problems. STUDY DESIGN AND PARTICIPANTS: Cross-sectional study of 165 participants (132 women, 33 men) with BMI ≥35 kg/m2 or ≥30 kg/m2 with comorbidities, enrolling in a multidisciplinary obesity treatment program.Entities:
Mesh:
Year: 2015 PMID: 26694031 PMCID: PMC4687938 DOI: 10.1371/journal.pone.0145273
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Anthropometric, sociodemographic and lifestyle characteristics in n = 165 treatment-seeking young adults (16–25 y) with obesity.
| Characteristic | Women (n = 132) | Men (n = 33) | Total (n = 165) |
|---|---|---|---|
|
| |||
| Age, y; mean (SD) | 19.6 (2.7) | 20.2 (2.8) | 19.7 (2.7) |
| Weight, kg; mean (SD) | 107.0 (14.3) | 133.9 (27.0) | 112.4 (20.6) |
| Body mass index, kg/m2; mean (SD) | 38.9 (4.9) | 40.3 (6.2) | 39.2 (5.2) |
| Body mass index classification; mean (SD) | |||
|
| 23 (17) | 5 (15) | 28 (17) |
|
| 59 (45) | 9 (27) | 68 (41) |
|
| 49 (37) | 18 (55) | 67 (41) |
| Waist circumference, cm; mean (SD) | 108.5 (10.3) | 126.7 (15.1) | 112.1 (13.5) |
|
| |||
|
| 83 (63) | 23 (70) | 106 (64) |
|
| 30 (23) | 3 (9) | 33 (20) |
|
| 11 (8) | 6 (18) | 17 (10) |
|
| 5 (4) | 0 (0) | 5 (3) |
|
| 14 (11) | 6 (19) | 20 (12) |
|
| 24 (18) | 7 (21) | 31 (19) |
|
| |||
|
| 113 (86) | 30 (91) | 143 (87) |
|
| 3 (2) | 1 (3) | 4 (2) |
|
| 3 (2) | 0 (0) | 3 (2) |
|
| 7 (5) | 2 (6) | 9 (6) |
|
| 3 (2) | 0 (0) | 3 (2) |
|
| 3 (2) | 0 (0) | 3 (2) |
|
| 24 (18) | 7 (21) | 31 (19) |
|
| |||
| Cardiorespiratory fitness, ml/kg/min; mean (SD) | 24.9 (5.2) | 23.0 (5.4) | 24.5 (5.3) |
|
| 57 (72) | 19 (100) | 76 (78) |
|
| 14 (18) | 0 (0) | 14 (14) |
|
| 5 (6) | 0 (0) | 5 (5) |
|
| 3 (4) | 0 (0) | 3 (3) |
| Daily tobacco smoker | 28 (21) | 8 (24) | 36 (22) |
| Cannabis, ever used | 20 (15) | 6 (18) | 26 (16) |
| Alcohol, units/week; median (IQR) | 1.0 (0.0–4.0) | 0.5 (0.0–3.5) | 1.0 (0.0–3.8) |
| Alcohol, hazardous drinking | 25 (19) | 2 (6) | 27 (17) |
| Karolinska Sleep Questionnaire [ | |||
|
| 1.7 (1.2) | 1.7 (1.2) | 1.7 (1.2) |
|
| 2.3 (1.4) | 2.4 (1.4) | 2.3 (1.4) |
|
| 0.6 (0.9) | 0.5 (0.7) | 0.6 (0.9) |
|
| 1.6 (1.2) | 1.5 (1.0) | 1.6 (1.2) |
|
| 69 (52) | 19 (58) | 88 (54) |
|
| 108 (83) | 27 (82) | 135 (83) |
a Both parents born outside Sweden and young adult born within Sweden.
b Astrand’s test [25]. nwomen = 79–88, nmen = 19–22.
c One unit = 12 g of 100% alcohol [45].
d Weekly consumption of 14 units for men and 9 units for women, or consumption of 5 units for men and 4 units for women at the same occasion, according to Swedish criteria [45].
Cardiometabolic risk factors, somatic disorders and micronutritional deficiencies in n = 165 treatment-seeking young adults (16–25 y) with obesity.
| Variable | Women (n = 132) | Men (n = 33) | Total (n = 165) |
|---|---|---|---|
|
| |||
| Fasting plasma-glucose, mmol/l; mean (SD) | 5.4 (1.6) | 5.3 (0.8) | 5.4 (1.5) |
| HbA1c, mmol/mol; mean (SD) | 35.4 (7.4) | 33.9 (5.7) | 35.1 (7.1) |
| Insulin, mlU/l; mean (SD) | 26.1 (22.4) | 28.7 (13.3) | 26.6 (20.9) |
| Total cholesterol, mmol/l; mean (SD) | 4.5 (0.9) | 4.6 (0.7) | 4.5 (0.9) |
| LDL cholesterol, mmol/l; mean (SD) | 2.8 (0.7) | 2.9 (0.7) | 2.8 (0.7) |
| HDL cholesterol, mmol/l; mean (SD) | 1.1 (0.2) | 1.0 (0.2) | 1.1 (0.2) |
| Fasting triglycerides, mmol/l; mean (SD) | 1.2 (0.6) | 1.6 (0.8) | 1.3 (0.6) |
| ALT, μkat/L; mean (SD) | 0.4 (0.3) | 1.0 (0.6) | 0.5 (0.5) |
| HOMA-IR; mean (SD) [ | 5.9 (3.8) | 7.1 (4.6) | 6.1 (4.0) |
|
| |||
| Diabetes mellitus type 2 | 3 (2) | 2 (6) | 5 (3) |
| Impaired fasting plasma-glucose (6.1–6.9 mmol/l) | 5 (4) | 0 | 5 (3) |
| Increased plasma-glucose (≥7 mmol/l) | 3 (2) | 0 | 3 (2) |
| Hypercholesterolemia | 4 (3) | 1 (3) | 5 (3) |
| Hypertension | 3 (2) | 1 (3) | 4 (2) |
| Polycystic ovary syndrome | 13 (10) | N/A | N/A |
| Non-alcoholic fatty liver disease | 0 (0) | 2 (6) | 2 (1) |
| Obstructive sleep apnea | 0 (0) | 0 (0) | 0 (0) |
| ≥1 of obesity-related metabolic disease | 19 (14) | 7 (21) | 26 (16) |
| Asthma | 28 (21) | 7 (21) | 35 (21) |
| Hypothyroidism | 10 (8) | 1 (3) | 11 (7) |
|
| |||
| Iron | |||
|
| 29 (22) | 5 (16) | 34 (22) |
|
| 26 (20) | 1 (3) | 27 (17) |
|
| 0 (0) | 0 (0) | 0 (0) |
| Serum-cobalamine | |||
|
| 30 (24) | 4 (13) | 34 (22) |
|
| 10 (8) | 2 (7) | 12 (8) |
| Blood-folate deficiency (<305 nmol/l) | 10 (9) | 0 (0) | 10 (7) |
| Serum-25-OH-Vitamin D | |||
|
| 61 (46) | 9 (32) | 70 (45) |
|
| 38 (29) | 17 (52) | 55 (35) |
| Serum-zinc deficiency (<10.7 πmol/l) | 10 (5) | 1 (4) | 11 (7) |
Abbreviations: LDL, low density lipoprotein; HDL, high density lipoprotein; ALT, alanine transferase; HOMA-IR, Homeostatic model assessment-Insulin resistance; N/A, not applicable.
a According to the definition by the World Health Organization [46].
b Diabetes mellitus type 2, hypercholesterolemia, hypertension, polycystic ovary syndrome, non-alcoholic fatty liver disease, obstructive sleep apnea.
c Reference values according to Beckman Coulter Inc (DxI, low cut-off) and Roche Diagnostics (Modular E120, high cut-off).
Psychiatric disorders, psychiatric medication, suicide attempts, mental health and health-related quality of life in n = 165 treatment-seeking young adults (16–25 y) with obesity.
| Variable | Women (n = 132) | Men (n = 33) | Total (n = 165) |
|---|---|---|---|
|
| |||
| Depressive episode | 21 (16) | 1 (3) | 22 (13) |
| Anxiety disorder | 16 (12) | 4 (12) | 20 (12) |
| ADHD-H/-I/-C | 14 (11) | 7 (21) | 21 (13) |
| Dyslexia | 24 (18) | 9 (27) | 33 (20) |
| Other neurodevelopmental disorders | 5 (4) | 3 (9) | 8 (5) |
| Eating disorder not otherwise specified | 2 (2) | 0 (0) | 2 (1) |
| ≥1 Psychiatric disorder present | 37 (28) | 10 (31) | 47 (29) |
| Life-time history of ≥1 psychiatric disorder | 47 (36) | 10 (30) | 57 (35) |
|
| |||
| Antidepressants | 19 (14) | 1 (3) | 20 (12) |
| Psychostimulants | 9 (7) | 4 (12) | 13 (8) |
| Sedatives | 10 (8) | 0 (0) | 10 (6) |
| Sleeping medication | 11 (8) | 4 (12) | 15 (9) |
| For any psychiatric disorder | 27 (21) | 8 (24) | 35 (21) |
|
| |||
|
| 114 (86) | 31 (94) | 145 (88) |
|
| 14 (11) | 1 (3) | 15 (9) |
|
| 4 (3) | 1 (3) | 5 (3) |
|
| 8.0 (4.6) | 6.9 (4.5) | 7.8 (4.6) |
|
| 68 (52) | 19 (58) | 87 (53) |
|
| 28 (21) | 7 (21) | 35 (21) |
|
| 35 (27) | 7 (21) | 42 (26) |
|
| 5.3 (4.3) | 5.1 (3.6) | 5.3 (4.1) |
|
| 96 (73) | 24 (73) | 120 (73) |
|
| 21 (16) | 7 (21) | 28 (17) |
|
| 15 (11) | 2 (6) | 17 (10) |
|
| 15.7 (7.0) | 18.3 (5.9) | 16.2 (6.9) |
|
| 58 (44) | 11 (33) | 69 (42) |
|
| 67.0 (27.0) | 50.6 (29.2) | 63.7 (28.1) |
|
| 20 (15) | 12 (36) | 32 (19) |
|
| 32 (24) | 10 (30) | 42 (25) |
|
| 80 (61) | 11 (33) | 91 (55) |
|
| 51 (39) | 10 (30) | 61 (37) |
|
| |||
|
| 46.0 (11.7) | 44.7 (9.0) | 45.7 (11.2) |
|
| 35.0 (14.0) | 39.4 (13.3) | 35.8 (13.9) |
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; -H, hyperactive-impulsive; -I, inattentive; -C, combined; HADS, Hospital anxiety and depression scale; ASRS, Adult ADHD Self-report Scale.
a Psychiatric disorders subclassified as in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition [20].
b Dyslexia and insomnia were excluded from the analysis.
c Serotonin reuptake inhibitor, serotonin noradrenaline reuptake inhibitor (ATC-code N06A).
d Metamphetamine, amphetamine, atomoxetin (ATC-code N06B).
e Benzodiazepine derivates, hydroxizine (ATC-code N05B).
f Benzodiazepine related drugs, melatonin (ATC-code N05C).
Multivariable regression analysis of factors independently associated with Hospital Anxiety and Depression Scale (HADS) in n = 165 treatment-seeking young adults (16–25 y) with obesity.
| Regression coefficient | 95% CI | P-value | |
|---|---|---|---|
|
| |||
|
| -0.057 | -0.22 to 0.10 | 0.48 |
|
| -0.12 | -0.27 to 0.036 | 0.13 |
|
| 2.4 | 0.82 to 4.00 | 0.003 |
|
| -0.25 | -0.37 to -0.13 | <0.001 |
|
| 0.014 | -0.015 to 0.044 | 0.34 |
|
| |||
|
| -0.039 | -0.18 to 0.099 | 0.57 |
|
| -0.18 | -0.31 to -0.045 | 0.009 |
|
| 0.65 | -0.74 to 2.03 | 0.36 |
|
| -0.23 | -0.33 to -0.12 | <0.001 |
|
| 0.031 | 0.005 to 0.058 | 0.018 |
Covariates: gender, age, economic strain, hazardous alcohol consumption, insomnia Homeostasis Model Assessment-Insulin resistance; and social support (all P>0.19). Adjusted R2 HADS-Anxiety = 0.33, P = <0.001; R2 HADS-Depression = 0.38, P = <0.001.
a Astrand´s test [25].
b European Quality of Life-5 Dimensions [42].
c Rosenberg Self-Esteem Scale [31].
d Obesity-related Problems Scale [33].